EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.
Over longer horizons, EBITDA CAGR averages 17.38% over 3 years; the trailing 12 months came in at -8.94%. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.
Medline Inc. (MDLN)
EBITDA growth vs the same quarter one year earlier, last 2 quarters.
Reported quarterly EBITDA; no daily interpolation.
| Year | Start EBITDA | End EBITDA | Change | % Change |
|---|---|---|---|---|
| 2025 | $3.20B | $2.92B | −$286.00M | -8.93% |
| 2024 | $2.40B | $3.20B | +$807.00M | +33.70% |
| 2023 | $1.80B | $2.40B | +$592.00M | +32.83% |
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Quarter ended Jun 2026 | $651.00M | -3.7% | -25.9% |
| Quarter ended Mar 2026 | $676.00M | +12.5% | -19.3% |
| Quarter ended Dec 2025 | $601.00M | -27.3% | N/A |
| Quarter ended Sep 2025 | $827.00M | -5.9% | N/A |
| Quarter ended Jun 2025 | $879.00M | +4.9% | N/A |
| Quarter ended Mar 2025 | $838.00M | N/A | N/A |
| Quarter ended Sep 2024 | $822.00M | +8.9% | N/A |
| Quarter ended Jun 2024 | $755.00M | N/A | N/A |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
